CervoMed Inc (CRVO)

Currency in USD
2.9300
-0.1400(-4.56%)
Closed·
2.93000.0000(0.00%)
·
CRVO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.91003.1900
52 wk Range
2.130011.2500
Key Statistics
Prev. Close
3.07
Open
3.11
Day's Range
2.91-3.19
52 wk Range
2.13-11.25
Volume
286.21K
Average Volume (3m)
5.59M
1-Year Change
-71.2463%
Book Value / Share
1.7
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRVO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.8000
Upside
+439.25%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

CervoMed Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.8000
(+439.25% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jones Trading
Buy12.00+309.56%20.00MaintainAug 10, 2026
Canaccord
Buy18.00+514.33%27.00MaintainAug 10, 2026
H.C. Wainwright
Buy25.00+753.24%-MaintainJul 15, 2026
H.C. Wainwright
Buy25.00+753.24%-MaintainJul 13, 2026
H.C. Wainwright
Buy25.00+753.24%-MaintainJul 09, 2026

Earnings

Latest Release
Aug 10, 2026
EPS / Forecast
-0.64 / -0.80
Revenue / Forecast
-- / 42.86K
EPS Revisions
Last 90 days

CRVO Income Statement

Compare CRVO to Peers and Sector

Metrics to compare
CRVO
Peers
Sector
Relationship
P/E Ratio
−1.5x−6.6x−0.4x
PEG Ratio
0.06−0.100.00
Price/Book
1.9x14.5x2.6x
Price / LTM Sales
133.7x5.9x3.1x
Upside (Analyst Target)
390.2%70.4%48.4%
Fair Value Upside
Unlock−12.5%6.5%Unlock

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
441.51K3.26%1.36M
Other Institutional Investors
2.18M16.09%6.68M
Public Companies & Retail Investors
10.91M80.65%33.49M
Total
13.53M100.00%41.53M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Heights Capital Management, Inc.5.54%750,0002,303
Morgan Stanley5.47%739,7362,271

People Also Watch

8.9000
ASTC
+2.06%
1.370
LASE
+7.87%
4.9100
MNTS
+1.03%
1.000
QTEX
-0.99%
10.8400
INHD
+57.33%

FAQ

What Is the CervoMed (CRVO) Stock Price Today?

The CervoMed stock price today is 2.9300 USD.

What Stock Exchange Does CervoMed Trade On?

CervoMed is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for CervoMed?

The stock symbol for CervoMed is "CRVO."

What Is the CervoMed Market Cap?

As of today, CervoMed market cap is 44.3000M USD.

What Is CervoMed's Earnings Per Share (TTM)?

The CervoMed EPS (TTM) is -3.1959.

When Is the Next CervoMed Earnings Date?

CervoMed will release its next earnings report on Nov 16, 2026.

From a Technical Analysis Perspective, Is CRVO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has CervoMed Stock Split?

CervoMed has split 5 times.

How Many Employees Does CervoMed Have?

CervoMed has 15 employees.

What is the current trading status of CervoMed (CRVO)?

As of Aug 14, 2026, CervoMed (CRVO) is trading at a price of 2.9300 USD, with a previous close of 3.0700 USD. The stock has fluctuated within a day range of 2.9100 USD to 3.1900 USD, while its 52-week range spans from 2.1300 USD to 11.2500 USD.

What Is CervoMed (CRVO) Price Target According to Analysts?

The average 12-month price target for CervoMed is 15.8000 USD, with a high estimate of 25 USD and a low estimate of 9 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +439.25% Upside potential.

What Is the CRVO Premarket Price?

CRVO's last pre-market stock price is 3.0900 USD. The pre-market share volume is 4,540.0000, and the stock has decreased by 0.0200, or 0.6500%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.